BACKGROUND: Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers. The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies. METHODS: Chemo-naive patients with histologically confirmed recurrent or metastatic carcinoma of salivary gland origin (mucoepidermoid, adenocarcinoma, or adenoid cystic) were eligible. Patients were treated with paclitaxel, 200 mg/m(2) IV, every 21 days for a minimum of four cycles. RESULTS: Forty-five patients were treated. Eight partial responses were seen among the 31 patients with mucoepidermoid or adenocarcinoma histologic findings for a response rate of 26%. No responses were seen in the adenoid cystic carcinoma group. No significant difference in overall survival was found among these three histologic subgroups. CONCLUSION: Paclitaxel demonstrates moderate activity in salivary gland tumors of mucoepidermoid and adenocarcinoma histology. The poor response rate in adenoid cystic carcinoma is consistent with prior reports in this chemoresistant histologic subtype. (c) 2005 Wiley Periodicals, Inc.
BACKGROUND:Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers. The Eastern Cooperative Oncology Group (ECOG) initiated a phase II evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies. METHODS: Chemo-naive patients with histologically confirmed recurrent or metastatic carcinoma of salivary gland origin (mucoepidermoid, adenocarcinoma, or adenoid cystic) were eligible. Patients were treated with paclitaxel, 200 mg/m(2) IV, every 21 days for a minimum of four cycles. RESULTS: Forty-five patients were treated. Eight partial responses were seen among the 31 patients with mucoepidermoid or adenocarcinoma histologic findings for a response rate of 26%. No responses were seen in the adenoid cystic carcinoma group. No significant difference in overall survival was found among these three histologic subgroups. CONCLUSION:Paclitaxel demonstrates moderate activity in salivary gland tumors of mucoepidermoid and adenocarcinoma histology. The poor response rate in adenoid cystic carcinoma is consistent with prior reports in this chemoresistant histologic subtype. (c) 2005 Wiley Periodicals, Inc.
Authors: Naresh Jegadeesh; Yuan Liu; Roshan S Prabhu; Kelly R Magliocca; David M Marcus; Kristin A Higgins; Jeffrey M Vainshtein; J Trad Wadsworth; Jonathan J Beitler Journal: Oral Oncol Date: 2015-05-29 Impact factor: 5.337
Authors: Masato Nakaguro; Yuichiro Tada; William C Faquin; Peter M Sadow; Lori J Wirth; Toshitaka Nagao Journal: Cancer Cytopathol Date: 2020-05-18 Impact factor: 5.284
Authors: Andrés Coca-Pelaz; Juan P Rodrigo; Asterios Triantafyllou; Jennifer L Hunt; Alessandra Rinaldo; Primož Strojan; Missak Haigentz; William M Mendenhall; Robert P Takes; Vincent Vander Poorten; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2014-04-26 Impact factor: 2.503
Authors: Diana Bell; Ehab Y Hanna; Lucio Miele; Dianna Roberts; Randal S Weber; Adel K El-Naggar Journal: Ann Diagn Pathol Date: 2013-10-10 Impact factor: 2.090
Authors: S J Wong; T Karrison; D N Hayes; M S Kies; K J Cullen; T Tanvetyanon; A Argiris; N Takebe; D Lim; N F Saba; F P Worden; J Gilbert; H J Lenz; A R A Razak; J D Roberts; E E Vokes; E E W Cohen Journal: Ann Oncol Date: 2015-11-23 Impact factor: 32.976
Authors: T Schneider; A Strehl; C Linz; R Brands; S Hartmann; F Beckford; A Rosenwald; A C Kübler; U D A Müller-Richter Journal: Clin Oral Investig Date: 2015-08-06 Impact factor: 3.573